These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10576529)

  • 41. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
    Goodarzi MO; Bryer-Ash M
    Diabetes Obes Metab; 2005 Nov; 7(6):654-65. PubMed ID: 16219009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Metformin: new data for an old molecule].
    Sanduloviciu M; Jornayvaz FR
    Rev Med Suisse; 2015 Jun; 11(477):1222-6. PubMed ID: 26211281
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metformin for schizophrenia: an editorial comment to Curtis J, Newall H, Shiers D, Samaras K. 'Considering metformin in cardiometabolic protection in psychosis'.
    Taylor D
    Acta Psychiatr Scand; 2012 Oct; 126(4):233-4. PubMed ID: 22974204
    [No Abstract]   [Full Text] [Related]  

  • 45. Is metformin more than an oral hypoglycaemic agent?
    Vague P
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S5-7. PubMed ID: 14502095
    [No Abstract]   [Full Text] [Related]  

  • 46. Mechanisms of action of metformin with special reference to cardiovascular protection.
    Zilov AV; Abdelaziz SI; AlShammary A; Al Zahrani A; Amir A; Assaad Khalil SH; Brand K; Elkafrawy N; Hassoun AAK; Jahed A; Jarrah N; Mrabeti S; Paruk I
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3173. PubMed ID: 31021474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?
    Scheen AJ
    Diabetes Care; 2003 Sep; 26(9):2701; author reply 2701-3. PubMed ID: 12941752
    [No Abstract]   [Full Text] [Related]  

  • 48. Should metformin be our antiglycemic agent of choice post-transplantation?
    Sharif A
    Am J Transplant; 2011 Jul; 11(7):1376-81. PubMed ID: 21564529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of diabetes: more answers, more questions.
    Misra A
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):831-2. PubMed ID: 26377053
    [No Abstract]   [Full Text] [Related]  

  • 50. Antiatherogenic properties of metformin: the experimental evidence.
    Mamputu JC; Wiernsperger NF; Renier G
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S71-6. PubMed ID: 14502103
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin effects revisited.
    Andújar-Plata P; Pi-Sunyer X; Laferrère B
    Diabetes Res Clin Pract; 2012 Jan; 95(1):1-9. PubMed ID: 22000494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
    Sonne DP; Knop FK
    Diabetes Care; 2015 Dec; 38(12):e215. PubMed ID: 26604291
    [No Abstract]   [Full Text] [Related]  

  • 53. [Metformin for prevention of diabetes?].
    Göke B
    Internist (Berl); 2000 May; 41(5):491. PubMed ID: 10867907
    [No Abstract]   [Full Text] [Related]  

  • 54. Response to Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
    Brandmaier S; Xu T; Illig T; Suhre K; Adamski J; Wang-Sattler R
    Diabetes Care; 2015 Dec; 38(12):e216-7. PubMed ID: 26604292
    [No Abstract]   [Full Text] [Related]  

  • 55. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
    Rydén L; Standl E
    N Engl J Med; 2022 Sep; 387(12):1136-1138. PubMed ID: 36130002
    [No Abstract]   [Full Text] [Related]  

  • 56. Rethinking the diabetes prevention program clinical trial.
    Singer F
    Diabetes Care; 1999 Oct; 22(10):1757. PubMed ID: 10526758
    [No Abstract]   [Full Text] [Related]  

  • 57. The effects of metformin on cardiovascular risk factors.
    Grant PJ
    Diabetes Metab Rev; 1995 Sep; 11 Suppl 1():S43-50. PubMed ID: 8529484
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin.
    Sattar N; McGuire DK
    Eur Heart J; 2021 Jul; 42(26):2574-2576. PubMed ID: 33200189
    [No Abstract]   [Full Text] [Related]  

  • 59. Diabetes: Cardiovascular benefits of metformin in T1DM.
    Snell-Bergeon JK
    Nat Rev Endocrinol; 2017 Oct; 13(10):565-566. PubMed ID: 28895950
    [No Abstract]   [Full Text] [Related]  

  • 60. Is Metformin Cardioprotective? A New Piece to the Puzzle.
    Dixon DL; Carbone S
    J Cardiovasc Pharmacol; 2024 Aug; 84(2):155-157. PubMed ID: 39115717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.